RCT: In Infants with infantile hemangioma, nadolol is noninferior to propranolol and may be an efficacious and safe alternative in cases of propranolol unresponsiveness or adverse events.

Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial – JAMA Pediatrics

Commentary: Oral Nadolol Feasible for the Treatment of Infantile Hemangiomas – HealthDay

Commentary on Twitter

A randomized clinical trial found #nadolol is non-inferior to #propranolol in patients with infantile hemangioma—a safe and efficacious alternative when fast response is needed https://t.co/ECVFfFPBJ2

— JAMA Pediatrics (@JAMAPediatrics) November 9, 2021